Shinichiro Takao - Hisamitsu Pharmaceutical Director
| HTSUF Stock | USD 25.22 0.00 0.00% |
Director
Mr. Shinichiro Takao was serving as Executive Officer, Chief Director of BU, Director of Finance, Manager of IR Office and Director in Hisamitsu Pharmaceutical Co., Inc., as well as President and Director of a subsidiary, since May 2016. He is also serving as Nonexecutive Director in an associated company, YUTOKU PHARMACEUTICAL INC. CO., LTD. He joined the Company in April 1978. since 2016.
| Age | 62 |
| Tenure | 8 years |
| Phone | 81 3 5293 1720 |
| Web | https://www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0504 %, meaning that it generated $0.0504 on every $100 dollars invested by stockholders. Hisamitsu Pharmaceutical's management efficiency ratios could be used to measure how well Hisamitsu Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 219 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hisamitsu Pharmaceutical has a current ratio of 4.37, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hisamitsu Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Hisamitsu Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hisamitsu Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hisamitsu to invest in growth at high rates of return. When we think about Hisamitsu Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Willard Dere | Mersana Therapeutics | 64 | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Russell Howard | Immutep Ltd ADR | 64 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| Lawrence Alleva | Mersana Therapeutics | 67 | |
| Frederic MD | Immutep Ltd ADR | 69 | |
| Eliyahu Zamir | Formula Systems 1985 | 46 | |
| Andrew Hack | Mersana Therapeutics | 43 | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| Pete Meyers | Immutep Ltd ADR | 46 | |
| Elizabeth Donnelly | Marker Therapeutics | N/A | |
| Rafal Kozlowski | Formula Systems 1985 | 41 | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Jay Gould | Provident Bancorp | N/A | |
| Eliahu Zamir | Formula Systems 1985 | 47 | |
| Frank Cousins | Provident Bancorp | 55 | |
| Mark Harrison | Home Federal Bancorp | 58 | |
| Marek Panek | Formula Systems 1985 | 45 | |
Management Performance
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 |
Hisamitsu Pharmaceutical Leadership Team
Elected by the shareholders, the Hisamitsu Pharmaceutical's board of directors comprises two types of representatives: Hisamitsu Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hisamitsu. The board's role is to monitor Hisamitsu Pharmaceutical's management team and ensure that shareholders' interests are well served. Hisamitsu Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hisamitsu Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hirotaka Nakatomi, Chairman, CEO and Chairman of Crisis Management Committee | ||
| Hidenori Hadate, Senior Managing Executive Officer | ||
| Tsuyoshi Ayabe, Executive Officer, Manager of Corporate Strategy Office | ||
| Toshiaki Tsuruda, Executive Officer, Chief Director of Production Environment, Director | ||
| Toshihide Kanari, Executive Officer, Director of External Affairs, Manager of Public Relations Office | ||
| Teijiro Furukawa, Non-Executive Independent Director | ||
| Takeshi Shakata, Executive Officer, Director of Drug and Cosmetics Business | ||
| Akira Kawata, Executive Officer | ||
| Shinichiro Takao, General Manager of IR Department, Treasurer and Director | ||
| Nobuo Tsutsumi, Executive Officer, Director of Legal Affairs, Director | ||
| Hiroyuki Taketomi, Executive Officer, Senior Director of Manufacturing, Director of General Affairs in Tosu Plant, Tosu Plant Manager | ||
| Katsuhiko Akiyama, Executive Officer, Director of Development Planning, Director of Base Research Institute | ||
| Tetsuo Akiyama, Managing Director and Director | ||
| Takeshi Masumoto, Executive Officer, Director of Kinki Supervision Unit in Pharmaceutical Business Unit | ||
| Kazuhide Nakatomi, President, COO and Executive VP | ||
| Isao Ichikawa, Non-Executive Independent Director | ||
| Shinichi Murayama, Executive Officer, Manager of President's Office in Kyushu Headquarters, Director | ||
| Akira Kayashima, Executive Officer | ||
| Mitsumasa Kabashima, Pres Ltd | ||
| Kyu Saito, Executive Officer, Director of International Business, Chairman of Subsidiaries, Director | ||
| Kiyotaka Takada, Executive Officer, Director of Production Technology Development | ||
| Mitsutoshi Tsuruta, Ex Division | ||
| Hidenao Minami, Executive Officer, Director of Clinical Development | ||
| Masaya Okuno, OTC Division | ||
| Takaaki Terahara, Executive Officer, Director of TDDS Research Institute, Manager of New Basic Technology Research Office, Manager of Patent Application Office | ||
| Naruhito Higo, Head of Research and Managing Director | ||
| Kotaro Sugimura, Executive Officer, Chief Director of Business, Manager of 1st Tokyo Office | ||
| Koji Takiyama, Executive Officer, Manager of President's Office | ||
| Kosuke Sugiyama, Senior Managing Director, Executive Officer, Director of Human Resource |
Hisamitsu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hisamitsu Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Hisamitsu Pink Sheet analysis
When running Hisamitsu Pharmaceutical's price analysis, check to measure Hisamitsu Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hisamitsu Pharmaceutical is operating at the current time. Most of Hisamitsu Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Hisamitsu Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hisamitsu Pharmaceutical's price. Additionally, you may evaluate how the addition of Hisamitsu Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |